U.S. Patent No. 10,258,601 B1 (‘601) issued on April 16, 2019, for “Vaporizable Cannabinoid Compositions.” It was issued to applicant/inventor Stephen C. Perry, of Norwood, Massachusetts. The specification discloses the composition of the vaporizable cannabis solution disclosed as comprising various Markush groups, including different formulations of the Cannabis plant, cannabinoids, bioactive ingredients, cannabinomimetics, and fatty alcohols. There are several embodiments describing different formulations of these groups. The claims are directed to the three composition formulations of cannabinoids, selected from the Markush group (MPEP 2117) of THC, CBD, CBN, CBG, and CBC, among others, and a carrier liquid solution comprising either glycerin or glycerol, ethanol, at least one lecithin and one fatty alcohol, and a liposome, with the additional composition claims further limiting either the group of fatty alcohol or the cannabinoid to only CBD. There is a further method claim directed to the process of inhaling the vaporizable cannabinoid composition.
There are no drawings disclosed in the patent disclosure.
The Cooperative Patent Classifications is A61K (preparations for medical, dental, or toilet purposes, namely, condensed carbocyclic rings, e.g., cannabinols (31/352); medicinal preparations characterized by special physical form, namely, aromatherapy (9/007); medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, e.g., traditional herbal medicines, like magnoliopsida (36/185), and Asteraceae or Compositae (36/28); and medicinal preparations characterized by non-active ingredients, e.g., carriers or inert additives, namely, esters of carboxylic acids, e.g., fatty acid monoglycerides (47/14)).
Please contact Yonaxis for more information on any of the IP processes described in this posting if you have any questions.